ArticleAntibiotics (Basel, Switzerland)2024
Isolation and Characterization of Novel Bacteriophages to Target Carbapenem-Resistant
Article in Antibiotics (Basel, Switzerland), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed.
- Virulence and Resistance Mechanisms in Multidrug-ResistantPathogens (Basel, Switzerland) · 2026Review
- Revisiting the Fight AgainstAntibiotics (Basel, Switzerland) · 2026Review
- A comprehensive analysis of the kinetics of infection of lytic bacteriophages specific to the ESKAPE and critical pathogens.World journal of microbiology & biotechnology · 2026Review
- Bentonite-Based Functional Nanoclay Enhances Bacteriophage Therapy against Enteric Infections via Toxin Adsorption and Microbiome Recovery.Biomaterials research · 2026Article
- Bacteriophages targetingFrontiers in microbiology · 2026Review
- Phage Therapy forAntibiotics (Basel, Switzerland) · 2025Review
- Overcoming phage resistance: efficacy of sequential phage-colistin therapy against carbapenem-resistantMicrobiology spectrum · 2025Article
- A Newly DiscoveredAntibiotics (Basel, Switzerland) · 2025Article
- Genomic characterization and pre-clinical evaluation of a new polyvalent lytic Loughborough phage.Applied microbiology and biotechnology · 2025Article
- Article
- In vitro, genomic characterization and pre-clinical evaluation of a new thermostable lytic Obolenskvirus phage formulated as a hydrogel against carbapenem-resistant Acinetobacter baumannii.Scientific reports · 2025Article
- Healthcare-Associated Infections: The Role of Microbial and Environmental Factors in Infection Control-A Narrative Review.Infectious diseases and therapy · 2025Review
- The challenges of difficult-to-treatClinical microbiology reviews · 2024Review
- Characterization of Newly Isolated Bacteriophages Targeting Carbapenem-Resistant Klebsiella pneumoniae.Journal of microbiology (Seoul, Korea) · 2024Article
- Synergistic Antimicrobial Effects of Phage vB_AbaSi_W9 and Antibiotics againstAntibiotics (Basel, Switzerland) · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
The spread of multidrug-resistant
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.